Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LY573636 as Third-line Treatment for Unresectable Metastatic Non-small Cell Lung Cancer
2006-002321-23Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tasisulam in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoints: Time to progressive disease and Progression-free survival distribution. Started May 2006; status: completed.
02
Drugs
tasisulam
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-002321-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002321-23.